U.S. markets closed
  • S&P Futures

    4,138.75
    -8.00 (-0.19%)
     
  • Dow Futures

    32,719.00
    -38.00 (-0.12%)
     
  • Nasdaq Futures

    13,204.00
    -24.75 (-0.19%)
     
  • Russell 2000 Futures

    1,918.40
    -3.40 (-0.18%)
     
  • Crude Oil

    88.78
    -0.23 (-0.26%)
     
  • Gold

    1,790.60
    -0.60 (-0.03%)
     
  • Silver

    19.84
    -0.00 (-0.01%)
     
  • EUR/USD

    1.0183
    -0.0004 (-0.04%)
     
  • 10-Yr Bond

    2.8400
    +0.1640 (+6.13%)
     
  • Vix

    21.15
    -0.29 (-1.35%)
     
  • GBP/USD

    1.2072
    +0.0001 (+0.01%)
     
  • USD/JPY

    135.3150
    +0.3450 (+0.26%)
     
  • BTC-USD

    23,248.95
    +289.97 (+1.26%)
     
  • CMC Crypto 200

    541.00
    +5.77 (+1.08%)
     
  • FTSE 100

    7,439.74
    -8.32 (-0.11%)
     
  • Nikkei 225

    28,207.02
    +31.15 (+0.11%)
     

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Dry Eye Disease Chamber Crossover Clinical Trial of Reproxalap

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

LEXINGTON, Mass., July 11, 2022--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, July 12, 2022, at 8:00 a.m. (ET) to report top-line results from the crossover clinical trial of reproxalap, an investigational new drug candidate, for the treatment of dry eye disease.

The dial-in numbers are (844) 200-6205 for domestic callers and (646) 904-5544 for international callers. The access code is 853619. A live audio webcast of the conference call also will be accessible from the "Investors & Media" section of Aldeyra's website at ir.aldeyra.com.

After the live webcast, the event will remain archived on Aldeyra’s website for 90 days.

About Aldeyra

Aldeyra develops innovative therapies designed to treat immune-mediated diseases. Our approach is to discover pharmaceuticals that modulate immunological systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokine, systems-based mediators of inflammation known as RASP (reactive aldehyde species). Reproxalap is in late-stage clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in Phase 2 clinical testing for the treatment of systemic immune-mediated diseases. Our pipeline also includes ADX-2191 (intravitreal methotrexate 0.8%), in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma. For more information, visit https://www.aldeyra.com and follow us on LinkedIn, Facebook, and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220711005532/en/

Contacts

Investor & Media:
Scott Solomon
Sharon Merrill Associates, Inc.
Tel: (857) 383-2409
ALDX@investorrelations.com